Comparison of serum fibroblast growth factor 23 (FGF23) levels and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) parameters in home hemodialysis and center hemodialysis
Abstract
Purpose: This study aims to compare serum fibroblast growth factor 23 (FGF23) levels and chronic kidney
disease-mineral and bone disorder (CKD-MBD) parameters in patients undergoing home hemodialysis (HHD)
and center hemodialysis (CHD).
Materials and methods: A total of 42 patients over 18 years old who had been receiving dialysis treatment for
at least six months were included in the study. The patients were divided into two groups: HHD (n=17) and CHD
(n=25). Demographic data, dialysis duration, biochemical parameters (serum phosphorus, calcium, parathyroid
hormone (PTH), albumin, hemoglobin, FGF23, etc.), and medication use were recorded. Serum FGF23 levels
were measured using an enzyme-linked immunosorbent assay (ELISA) method from blood samples taken
before midweek HD sessions. Frequency distributions were expressed as percentages and compared using
the chi-square test.
Results: The Kt/V values were higher in the HHD group (2.4±0.1 vs. 1.6±0.1), while serum phosphorus levels
were lower (4.1±1.1 vs. 5.0±1.2 mg/dL). Although FGF23 levels were lower in the HHD group, the difference was
not statistically significant (383±423 vs. 441±480 pg/mL, p=0.05). Erythropoietin (Epo) usage was significantly
lower in the HHD group (47% vs. 92%, p=0.001).
Conclusion: HHD was associated with better phosphorus control and a reduced requirement for EPO
compared to CHD. The lower FGF23 levels in HHD suggest that this modality may offer advantages in CKD-
MBD, cardiovascular outcomes, and mortality. However, these findings need to be supported by prospective
studies involving larger patient populations.
Keywords
FGF23, home hemodialysis, center hemodialysis, chronic kidney disease, dialysis
References
- 1. Trinh E, Chan CT. The Rise, Fall, and Resurgence of Home Hemodialysis. Semin Dial. 2017;30(2):174-180. doi:10.1111/sdi.12572
- 2. Lacson E Jr, Xu J, Suri RS, et al. Survival with three-times weekly in-center nocturnal versus conventional hemodialysis. J Am Soc Nephrol. 2012;23(4):687-695. doi:10.1681/ASN.2011070674
- 3. Ok E, Duman S, Asci G, et al. Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study. Nephrol Dial Transplant. 2011;26(4):1287-1296. doi:10.1093/ndt/gfq724
- 4. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998;53(5):1399-1404. doi:10.1046/j.1523-1755.1998.00875.x
- 5. Goodkin DA, Bragg Gresham JL, Koenig KG, et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol. 2003;14(12):3270-3277. doi:10.1097/01.asn.0000100127.54107.57
- 6. Bugeja A, Dacouris N, Thomas A, et al. In-center nocturnal hemodialysis: another option in the management of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):778-783. doi:10.2215/CJN.05221008
- 7. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009;302(16):1782-1789. doi:10.1001/jama.2009.1488
- 8. Martin A, David V, Quarles LD. Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev. 2012;92(1):131-155. doi:10.1152/physrev.00002.2011
- 9. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314(2):409-414. doi:10.1016/j.bbrc.2003.12.1021
- 10. Galitzer H, Ben Dov IZ, Silver J, Naveh Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 2010;77(3):211-218. doi:10.1038/ki.2009.464
